CPT℠ management continues to monitor our comprehensive approach assessing our readiness across all critical departmental functions, during the evolving situation surrounding COVID-19 and Executive Orders 107 and 108 (effective Saturday 3/21/20) and Executive Order 119 (effective Tuesday 4/7/20) in New Jersey.

CPT℠ remains committed to ensuring our clients get the personalized service which is our hallmark, combined with the ethical generation of data essential to your business. The well-being of our staff, subject population, clients and suppliers is our primary concern.

To achieve this, we have:

  • Enhanced our compliance with CDC, WHO and governmental authority recommendations
  • Enabled remote access capabilities with our vetted IT systems for employees, and video conferencing with clients, auditors and monitors
  • Started shift planning to reduce staff density while maintaining work throughput
  • Continued to refine our business continuity planning and the readiness of our laboratories and staff
  • Daily review and implementation of best practices
  • Current Impact on Operations

We are not experiencing delays in initiation of testing in our Analytical Chemistry, Microbiology, In-Vitro Photobiology and In-Vitro Toxicology laboratories. CPT℠ has no plans to temporarily discontinue those operations at this time. We are providing critical services and consultation to our clients in the pharmaceutical, therapeutic, medical device and personal care industries. We continue to monitor and adapt as quickly as possible to the rapidly changing situation. Should our situation change, we will be notifying you of further developments.

Note that based upon our compliance with Executive Order 107 and 108 here in NJ, we have temporarily discontinued the initiation of In-Vivo Photobiology and Clinical trials at this time. The well-being of our staff and subject population is our primary concern. We had previously instituted measures consistent with the CDC, WHO and local government and health recommendations. Our compliance with the E.O. ensures appropriate protections for both our team members and our subject population.

The Clinical management team is assessing the status of ongoing studies, and you will be contacted to ensure that your Photobiology or Clinical trial is closed out to the best of our ability where possible, or restarted when we reopen. Studies in our queue are postponed and you will be contacted with future start dates once we have clarity on when we can reopen. In the meantime, the Clinical team continues to work on studies in our queue, developing protocols and CRFs to meet client expectations. Please be patient while we go through this process.

Should you have any questions, please contact your CPT℠ Account Manager or Client Services. If you are not signed up for eCPT℠ client access system, please contact Client Services.

Thank you for your continued support. Through all of this, we are re-emphasizing what is most important – our team members, our communities and you.

Lon Weiss
Co-CEO and Chief Operating Officer
CPT℠ Labs